Products Mitapivat + Mitapivat-matching placebo
Mitapivat + Mitapivat-matching placebo Phase 3 Active 💤 Quiet Interest: 38/100
Pediatric Pyruvate Kinase Deficiency
Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Jun 8, 2022 → Jun 1, 2029
About Mitapivat + Mitapivat-matching placebo Mitapivat + Mitapivat-matching placebo is a phase 3 stage product being developed by Agios Pharmaceuticals for Pediatric Pyruvate Kinase Deficiency. The current trial status is active. This product is registered under clinical trial identifier NCT05144256. Target conditions include Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia.
What happened to similar drugs? 3 of 18 similar drugs in Pediatric Pyruvate Kinase Deficiency were approved
Clinical Trials (2) NCT ID Phase Status Start Completion Indication NCT05144256 Phase 3 Active Jun 8, 2022 Jun 1, 2029 Pediatric Pyruvate Kinase Deficiency NCT05175105 Phase 3 Active Jun 6, 2022 Jan 1, 2030 Pediatric Pyruvate Kinase Deficiency
Competing Products 20 competing products in Pediatric Pyruvate Kinase Deficiency
See all competitors Product Company Stage Hype Score Ramucirumab Eli Lilly Phase 1 erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome + Irinotecan + Vincristine Sun Pharmaceutical Phase 1 Perampanel Oral Suspension + Perampanel Tablet Eisai Phase 2 Eribulin Mesylate Eisai Phase 1 Decitabine + Decitabine Eisai Phase 2 Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily Sumitomo Pharma Phase 1 Remimazolam Tosilate for injection + Propofol Injection Jiangsu Hengrui Medicine Phase 2/3 Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid AstraZeneca Phase 2/3 candsartan cilexetil AstraZeneca Phase 3 Durvalumab / Tremelimumab Combination Therapy AstraZeneca Phase 1/2 Rotavirus Vaccine Merck Pre-clinical basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroids Novartis Phase 3 VAL489 + VAL489 matching placebo Novartis Phase 3 LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696 Novartis Phase 2/3 Everolimus Novartis Phase 2 Corticosteroids + Cyclosporine + mycophenolate mofetil Roche Phase 2 Entecavir + Lamivudine + Pegylated Interferon Alfa-2A Roche Phase 3 Blinatumomab for Injection Amgen Phase 1 Etanercept Amgen Phase 3